Abstract
Introduction: The integration between radiotherapy and drugs, from chemotherapy to recently available target therapies, continues to have a relevant role in the treatment of locally advanced and metastatic Non-small cell lung cancer (NSCLC). Aim of the present review is to evaluate the promising and emerging application of the best interaction between new drugs and new modalities of radiotherapy. Areas covered: We searched Medline, Google Scholar, PubMed, ProQuest Dissertation, and Theses databases for reports published in English. A study was included when it reported on cancer-related radiotherapy and included patients with NSCLC treated with chemo and/or target therapies. Review articles were excluded from the analysis. Expert commentary: Chemo-radiotherapy still represents the standard of choice in locally advanced NSCLC, while to date the addition of target therapies to chemo-radiotherapy did not demonstrate any robust advantage in this stage of disease. Considering the absence of randomized controlled trials, the role of target therapies in early stage adjuvant NSCLC is not yet recommended in clinical practice. On the contrary, in the setting of oligometastatic and oligoprogressive disease, new molecules demonstrated to be safe and effective, opening to a promising and emerging application of the best interaction between new drugs and new modalities of radiotherapy.
| Original language | English |
|---|---|
| Pages (from-to) | 157-165 |
| Number of pages | 9 |
| Journal | Expert Review of Anticancer Therapy |
| Volume | 17 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Feb 1 2017 |
Fingerprint
Keywords
- early stage
- locally advanced
- Lung cancer
- oligometastatic
- radiotherapy
- target therapies
ASJC Scopus subject areas
- Oncology
- Pharmacology (medical)
Cite this
From chemotherapy to target therapies associated with radiation in the treatment of NSCLC : a durable marriage? / Alongi, Filippo; Arcangeli, Stefano; Ramella, Sara; Giaj-Levra, Niccolò; Borghetti, Paolo; D’angelillo, Rolando; Ricchetti, Francesco; Maddalo, Marta; Mazzola, Rosario; Trovò, Marco; Russi, Elvio; Magrini, Stefano Maria; on the behalf of Associazione Italiana Radioterapia Oncologica (AIRO), the behalf of Associazione Italiana Radioterapia Oncologica (AIRO).
In: Expert Review of Anticancer Therapy, Vol. 17, No. 2, 01.02.2017, p. 157-165.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - From chemotherapy to target therapies associated with radiation in the treatment of NSCLC
T2 - a durable marriage?
AU - Alongi, Filippo
AU - Arcangeli, Stefano
AU - Ramella, Sara
AU - Giaj-Levra, Niccolò
AU - Borghetti, Paolo
AU - D’angelillo, Rolando
AU - Ricchetti, Francesco
AU - Maddalo, Marta
AU - Mazzola, Rosario
AU - Trovò, Marco
AU - Russi, Elvio
AU - Magrini, Stefano Maria
AU - on the behalf of Associazione Italiana Radioterapia Oncologica (AIRO), the behalf of Associazione Italiana Radioterapia Oncologica (AIRO)
PY - 2017/2/1
Y1 - 2017/2/1
N2 - Introduction: The integration between radiotherapy and drugs, from chemotherapy to recently available target therapies, continues to have a relevant role in the treatment of locally advanced and metastatic Non-small cell lung cancer (NSCLC). Aim of the present review is to evaluate the promising and emerging application of the best interaction between new drugs and new modalities of radiotherapy. Areas covered: We searched Medline, Google Scholar, PubMed, ProQuest Dissertation, and Theses databases for reports published in English. A study was included when it reported on cancer-related radiotherapy and included patients with NSCLC treated with chemo and/or target therapies. Review articles were excluded from the analysis. Expert commentary: Chemo-radiotherapy still represents the standard of choice in locally advanced NSCLC, while to date the addition of target therapies to chemo-radiotherapy did not demonstrate any robust advantage in this stage of disease. Considering the absence of randomized controlled trials, the role of target therapies in early stage adjuvant NSCLC is not yet recommended in clinical practice. On the contrary, in the setting of oligometastatic and oligoprogressive disease, new molecules demonstrated to be safe and effective, opening to a promising and emerging application of the best interaction between new drugs and new modalities of radiotherapy.
AB - Introduction: The integration between radiotherapy and drugs, from chemotherapy to recently available target therapies, continues to have a relevant role in the treatment of locally advanced and metastatic Non-small cell lung cancer (NSCLC). Aim of the present review is to evaluate the promising and emerging application of the best interaction between new drugs and new modalities of radiotherapy. Areas covered: We searched Medline, Google Scholar, PubMed, ProQuest Dissertation, and Theses databases for reports published in English. A study was included when it reported on cancer-related radiotherapy and included patients with NSCLC treated with chemo and/or target therapies. Review articles were excluded from the analysis. Expert commentary: Chemo-radiotherapy still represents the standard of choice in locally advanced NSCLC, while to date the addition of target therapies to chemo-radiotherapy did not demonstrate any robust advantage in this stage of disease. Considering the absence of randomized controlled trials, the role of target therapies in early stage adjuvant NSCLC is not yet recommended in clinical practice. On the contrary, in the setting of oligometastatic and oligoprogressive disease, new molecules demonstrated to be safe and effective, opening to a promising and emerging application of the best interaction between new drugs and new modalities of radiotherapy.
KW - early stage
KW - locally advanced
KW - Lung cancer
KW - oligometastatic
KW - radiotherapy
KW - target therapies
UR - http://www.scopus.com/inward/record.url?scp=85010908821&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85010908821&partnerID=8YFLogxK
U2 - 10.1080/14737140.2017.1273111
DO - 10.1080/14737140.2017.1273111
M3 - Review article
C2 - 27984919
AN - SCOPUS:85010908821
VL - 17
SP - 157
EP - 165
JO - Expert Review of Anticancer Therapy
JF - Expert Review of Anticancer Therapy
SN - 1473-7140
IS - 2
ER -